Cargando…

Harnessing Immune Response in Acute Myeloid Leukemia

Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory (R/R) disease or elderly/unfit patients. Among...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riva, Carola, Vernarecci, Chiara, Minetto, Paola, Goda, Rayan, Greppi, Marco, Pesce, Silvia, Chies, Maria, Zecchetti, Giada, Ferro, Beatrice, Maio, Elena, Cea, Michele, Lemoli, Roberto Massimo, Marcenaro, Emanuela, Guolo, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532363/ https://www.ncbi.nlm.nih.gov/pubmed/37762763 http://dx.doi.org/10.3390/jcm12185824

Ejemplares similares

P530: CPX-351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION
por: Riva, Carola, et al.
Publicado: (2023)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Vernarecci, Chiara, et al.
Publicado: (2023)

Harnessing NK Cells for Cancer Treatment
por: Minetto, Paola, et al.
Publicado: (2019)

P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE
por: Maio, Elena, et al.
Publicado: (2023)

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
por: Pesce, Silvia, et al.
Publicado: (2020)

S217: POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION
por: Guolo, Fabio, et al.
Publicado: (2023)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Identification of a novel cord blood NK cell subpopulation expressing functional programmed death receptor-1
por: Greppi, Marco, et al.
Publicado: (2023)

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
por: Guolo, Fabio, et al.
Publicado: (2021)

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells’ vulnerability to DNA-damaging agents
por: Cagnetta, Antonia, et al.
Publicado: (2018)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

New Insights into Endometrial Cancer
por: Paleari, Laura, et al.
Publicado: (2021)

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs
por: Soncini, Debora, et al.
Publicado: (2019)

Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer
por: Greppi, Marco, et al.
Publicado: (2019)

Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
por: Provinciali, Nicoletta, et al.
Publicado: (2022)

New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression
por: Pesce, Silvia, et al.
Publicado: (2018)

miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
por: Pesce, Silvia, et al.
Publicado: (2020)

Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance
por: Ferretti, Elisa, et al.
Publicado: (2020)

Editorial: Precision medicine for acute myeloid leukemia
por: Marconi, Giovanni, et al.
Publicado: (2023)

Female Malignancies and Immunotherapy: What’s New?
por: Pesce, Silvia, et al.
Publicado: (2020)

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands
por: Pesce, Silvia, et al.
Publicado: (2017)

TLR/NCR/KIR: Which One to Use and When?
por: Sivori, Simona, et al.
Publicado: (2014)

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
por: Minetto, Paola, et al.
Publicado: (2020)

Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor
por: Pesce, Silvia, et al.
Publicado: (2016)

Case Report: A Peculiar Case of Inflammatory Colitis After SARS-CoV-2 Infection
por: Rutigliani, Mariangela, et al.
Publicado: (2022)

Harnessing the Metabolic Vulnerabilities of Leukemia Stem Cells to Eradicate Acute Myeloid Leukemia
por: Kumar, Bijender
Publicado: (2021)

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
por: Hsieh, Ya-Ching, et al.
Publicado: (2021)

NK Cell-Based Immunotherapy in Colorectal Cancer
por: Della Chiesa, Mariella, et al.
Publicado: (2022)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Uptake of CCR7 by KIR2DS4(+) NK Cells Is Induced upon Recognition of Certain HLA-C Alleles
por: Pesce, Silvia, et al.
Publicado: (2015)

Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia
por: Melo Garcia, Luciana, et al.
Publicado: (2021)

Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis
por: Pesce, Silvia, et al.
Publicado: (2019)

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma
por: Gelli, Elisa, et al.
Publicado: (2023)

A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans
por: Rebaudi, Federico, et al.
Publicado: (2023)

Harnessing Mechanosensation in Next Generation Cardiovascular Tissue Engineering
por: Garoffolo, Gloria, et al.
Publicado: (2020)

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire
por: Meazza, Raffaella, et al.
Publicado: (2023)

Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
por: Clappaert, Emile J., et al.
Publicado: (2018)

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
por: Soncini, Debora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rbg8enihubs90ada5h9ujq3s2j